Become A Wiser, More Profitable Investor

✅   Repurposing Quetiapine as an Adjuvant Therapeutic Agent for Triple-Negative Breast Cancer

science

Background: The lack of a molecular target in triple-negative breast cancer (TNBC) makes it one of the most challenging breast cancers to treat. Current standard-of-care primarily relies on cytotoxic chemotherapy and radiotherapy, but long-term outcomes remain poor largely due to early relapse, therapy resistance, and high incidents of metastases. More recently, dopamine signaling has emerged as a novel area of interest in cancer biology. Dopamine receptors have been implicated in tumor progression, maintenance of cancer stem-like cells, and therapy resistance in various malignancies, including TNBC. Quetiapine (QTP), an FDA-approved atypical antipsychotic and DRD2/DRD3 antagonist, has shown preclinical efficacy in glioblastoma. However, its anti-tumor potential in TNBC remains unexplored.

BioRxiv     Apr 25, 2025